New NCCN Patient Resource Shares Latest Understanding of Genetic Testing to Guide Patient Decision Making
Free information from the National Comprehensive Cancer Network offers information on how…
New NCCN Patient Resource Shares Latest Understanding of Genetic Testing to Guide Patient Decision Making
Free information from the National Comprehensive Cancer Network offers information on how…
New NCCN Patient Resource Shares Latest Understanding of Genetic Testing to Guide Patient Decision Making
Free information from the National Comprehensive Cancer Network offers information on how…
New NCCN Patient Resource Shares Latest Understanding of Genetic Testing to Guide Patient Decision Making
Free information from the National Comprehensive Cancer Network offers information on how…
New NCCN Patient Resource Shares Latest Understanding of Genetic Testing to Guide Patient Decision Making
Free information from the National Comprehensive Cancer Network offers information on how…
New NCCN Patient Resource Shares Latest Understanding of Genetic Testing to Guide Patient Decision Making
Free information from the National Comprehensive Cancer Network offers information on how…
Myriad Genetics RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.…
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence…
Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary Risk
National Comprehensive Cancer Network overhauls two major resources to help cancer care…